About
CraniUS Therapeutics is a neurotechnology and medical device company based in Baltimore, Maryland, founded in 2021. The company specializes in advanced intracranial drug delivery systems aimed at treating chronic brain diseases. Under the leadership of Dr. Chad Gordon, CraniUS has developed the NeuroPASS™ device, the first smart, refillable, fully implantable medical device designed to bypass the blood-brain barrier. This innovative device allows for precise delivery of therapeutics directly to targeted brain regions, enhancing treatment efficacy while minimizing adverse effects. Currently in pre-clinical development, NeuroPASS is progressing toward FDA pre-clinical studies, with plans for Investigational New Drug (IND) approval for first-in-human trials expected in early 2025. CraniUS has secured multiple patents and raised over $24 million in funding, including a grant from the State of Maryland’s innovation program. The company aims to serve patients with chronic brain diseases and contribute to the medical and research community focused on neurotherapeutics, positioning itself at the forefront of the brain-medicine interface field.
Technologies
Keywords
Company Information
-
Employees 16
-
Total Funding $20400000
Location
1700 Union Ave, Baltimore, Maryland, United States, 21211
